Oxford Biomedica’s shares have plummeted 37% from their January high, raising questions about their current value. While the company anticipates a loss in the first half of the year due to revenue phasing and planned shutdowns, it projects a turnaround with significant revenue growth expected in the latter half. Analysts foresee an average yearly profit growth of 75.3% through 2029, suggesting the stock may be undervalued. Current assessments indicate a potential fair value more than three times its present price, making it a speculative yet attractive option for long-term investors. Simon Watkins, a shareholder, plans to buy more shares amid the current dip.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.twelfthmagpie.com/2026/06/22/just-above-6-today-heres-where-this-deeply-undervalued-ftse-biotech-star-should-be-trading-right-now/
